Pharma should make 'the private public' to boost research, industry execs conclude

7 September 2010

Last week, executives from companies including AstraZeneca, GlaxoSmithKline, Johnson & Johnson, Pfizer and Roche met in Vienna, Austria, in a closed meeting to discuss the future of the pharmaceutical industry. Fears of layoffs at drugmakers are once again dominating the news - notably last week with Roche's announcement of its 'operational excellence' initiative (The Pharma Letter September 6), but could there be a less painful way to save money?

Attendees at the Next Generation Pharmaceutical Drug Discovery Summit (hosted by GDS International) were among those leading the rumors of job cuts within the drug discovery arena, but this was far from being their main focus. Despite the obvious fears and dangers, the consensus was that the only way forward was to continue looking towards the future.

Temporary partnerships mooted

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK